MicroRNA-133b is regulated by TAp63 while no gene mutation is present in colorectal cancer

Chen,Yifei; Zhang,Yi; He,Jianhuai; Fu,Ying; Lin,Changwei; Li,Xiaorong

doi:10.3892/or.2017.5371

MicroRNA-133b is regulated by TAp63 while no gene mutation is present in colorectal cancer

Authors:
- Yifei Chen
- Yi Zhang
- Jianhuai He
- Ying Fu
- Changwei Lin
- Xiaorong Li
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, The Third XiangYa Hospital of Central South University, Changsha, Hunan 410013, P.R. China, Department of Oncological Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, P.R. China, Department of Breast, Thyroid and Vascular Surgery, Chenzhou No. 1 People's Hospital, Chenzhou, Hunan 423000, P.R. China
Published online on: January 16, 2017 https://doi.org/10.3892/or.2017.5371
Pages: 1646-1652

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Downregulation of miR-133b has been reported in multiple types of malignancies including colorectal cancer (CRC). We previously confirmed that TAp63 actively translates microRNA-133b (miR-133b) transcripts. While the presence of miRNA mutations have frequently been described in CRC, most CRCs do not show any variation in the miR‑133b coding sequence. Therefore, it is important to elucidate the relationship between TAp63 and miR-133b, and identify other mediators of miR-133b downregulation in CRC. The expression of TAp63 was detected by RT-qPCR, western blotting, immunohistochemistry (IHC) and densitometric analysis using Image-Pro Plus 6.0 software in 38 CRC and corresponding non-cancerous tissues (NCTs). The expression of mature miR‑133b was determined by RT-qPCR, in situ hybridization (ISH) and densitometric analysis using Image-Pro Plus 6.0 software. The DNA from 38 CRC tissues and NCTs were screened for miR-133b mutations through sequence analysis. Compared with the NCTs, TAp63 mRNA expression was significantly lower in 21 (55.27%) tumor tissues. Compared with the NCTs, the miR‑133b expression level was significantly lower in 31 (81.58%) tumor tissues. The expression of miR‑133b was found to be positively correlated with TAp63. Loss of TAp63 and miR-133b was associated with an increased likelihood of metastatic events. The area under the ROC curve (AUC) of TAp63 for CRC was 0.623 [95% confidence interval (CI), 0.497-0.748; P=0.046], with 73.7% sensitivity and 50% specificity, respectively. The AUC of miR-133b for CRC was 0.857 (95% CI, 0.774‑0.940; P<0.0001), with 78.9% sensitivity and 81.6% specificity, respectively. The combined AUC of TAp63 and miR-133b for CRC was 0.881 (95% CI, 0.805-0.956; P<0.0001), with 89.5% sensitivity and 71.1% specificity, respectively. Point mutations within the seed region of miR-133b were found in 1 patient, but the point mutation did not impact the secondary structure of the pre-miR-133b. Therefore, downregulation of TAp63 may be one reason for the dysregulation of miR‑133b in CRC. The expression analysis of TAp63 and miR-133b revealed that they may be used as valuable prognostic biomarkers for CRC.

View Figures

View References

1	Abu-Amero KK, Helwa I, Al-Muammar A, Strickland S, Hauser MA, Allingham RR and Liu Y: Screening of the seed region of MIR184 in keratoconus patients from Saudi Arabia. Biomed Res Int. 2015:6045082015. View Article : Google Scholar : PubMed/NCBI
2	Cristobal I, Madoz-Gurpide J, Martin-Aparicio E, Carames C, Aguilera O, Rojo F and Garcia-Foncillas J: Comment on ‘TAp63 suppress metastasis via miR-133b in colon cancer cells’. Br J Cancer. 111:23692014. View Article : Google Scholar : PubMed/NCBI
3	Kubisch J, Türei D, Földvári-Nagy L, Dunai ZA, Zsákai L, Varga M, Vellai T, Csermely P and Korcsmáros T: Complex regulation of autophagy in cancer - integrated approaches to discover the networks that hold a double-edged sword. Semin Cancer Biol. 23:252–261. 2013. View Article : Google Scholar : PubMed/NCBI
4	Shih IM and Kurman RJ: p63 expression is useful in the distinction of epithelioid trophoblastic and placental site trophoblastic tumors by profiling trophoblastic subpopulations. Am J Surg Pathol. 28:1177–1183. 2004. View Article : Google Scholar : PubMed/NCBI
5	Bassampour SA, Abdi R, Bahador R, Shakeri M, Torkaman A, Yahaghi E and Taheriazam A: Downregulation of miR-133b/miR-503 acts as efficient prognostic and diagnostic factors in patients with osteosarcoma and these predictor biomarkers are correlated with overall survival. Tumour Biol. Aug 16–2015.(Epub ahead of print). PubMed/NCBI
6	Guzel E, Karatas OF, Semercioz A, Ekici S, Aykan S, Yentur S, Creighton CJ, Ittmann M and Ozen M: Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer. Int J Cancer. 136:875–879. 2015. View Article : Google Scholar : PubMed/NCBI
7	Duan FT, Qian F, Fang K, Lin KY, Wang WT and Chen YQ: miR-133b, a muscle-specific microRNA, is a novel prognostic marker that participates in the progression of human colorectal cancer via regulation of CXCR4 expression. Mol Cancer. 12:1642013. View Article : Google Scholar : PubMed/NCBI
8	Zhao Y, Huang J, Zhang L, Qu Y, Li J, Yu B, Yan M, Yu Y, Liu B and Zhu Z: MiR-133b is frequently decreased in gastric cancer and its overexpression reduces the metastatic potential of gastric cancer cells. BMC Cancer. 14:342014. View Article : Google Scholar : PubMed/NCBI
9	Li X, Wan X, Chen H, Yang S, Liu Y, Mo W, Meng D, Du W, Huang Y, Wu H, et al: Identification of miR-133b and RB1CC1 as independent predictors for biochemical recurrence and potential therapeutic targets for prostate cancer. Clin Cancer Res. 20:2312–2325. 2014. View Article : Google Scholar : PubMed/NCBI
10	Ellermeier C, Vang S, Cleveland K, Durand W, Resnick MB and Brodsky AS: Prognostic microRNA expression signature from examination of colorectal primary and metastatic tumors. Anticancer Res. 34:3957–3967. 2014.PubMed/NCBI
11	Akçakaya P, Ekelund S, Kolosenko I, Caramuta S, Ozata DM, Xie H, Lindforss U, Olivecrona H and Lui WO: miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer. Int J Oncol. 39:311–318. 2011.PubMed/NCBI
12	Das RK, Anura A, Pal M, Bag S, Majumdar S, Barui A, Chakraborty C, Ray AK, Sengupta S, Paul RR, et al: Epithelio-mesenchymal transitional attributes in oral sub-mucous fibrosis. Exp Mol Pathol. 95:259–269. 2013. View Article : Google Scholar : PubMed/NCBI
13	Zhang Y, Yan W and Chen X: P63 regulates tubular formation via epithelial-to-mesenchymal transition. Oncogene. 33:1548–1557. 2014. View Article : Google Scholar : PubMed/NCBI
14	Celardo I, Grespi F, Antonov A, Bernassola F, Garabadgiu AV, Melino G and Amelio I: Caspase-1 is a novel target of p63 in tumor suppression. Cell Death Dis. 4:e6452013. View Article : Google Scholar : PubMed/NCBI
15	Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vousden KH, Muller PA, Dötsch V, Kehrloesser S, Sayan BS, et al: Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci USA. 109:15312–15317. 2012. View Article : Google Scholar : PubMed/NCBI
16	Lin CW, Li XR, Zhang Y, Hu G, Guo YH, Zhou JY, Du J, Lv L, Gao K, Zhang Y, et al: TAp63 suppress metastasis via miR-133b in colon cancer cells. Br J Cancer. 110:2310–2320. 2014. View Article : Google Scholar : PubMed/NCBI
17	Gao QW, Hua LD, Wang J, Fan CX, Deng WY, Li B, Bian WJ, Shao CX, He N, Zhou P, et al: A point mutation in SCN1A 5 genomic region decreases the promoter activity and is associated with mild epilepsy and seizure aggravation induced by antiepileptic drug. Mol Neurobiol. Mar 11–2016.(Epub ahead of print). View Article : Google Scholar
18	Brooks MB, Catalfamo JL, MacNguyen R, Tim D, Fancher S and McCardle JAA: A TMEM16F point mutation causes an absence of canine platelet TMEM16F and ineffective activation and death-induced phospholipid scrambling. J Thromb Haemost. 13:2240–2252. 2015. View Article : Google Scholar : PubMed/NCBI
19	Tan X, Wang H, Luo G, Ren S, Li W, Cui J, Gill HS, Fu SW and Lu Y: Clinical significance of a point mutation in DNA polymerase beta (POLB) gene in gastric cancer. Int J Biol Sci. 11:144–155. 2015. View Article : Google Scholar : PubMed/NCBI
20	Lee HC, Yang CW, Chen CY and Au LC: Single point mutation of microRNA may cause butterfly effect on alteration of global gene expression. Biochem Biophys Res Commun. 404:1065–1069. 2011. View Article : Google Scholar : PubMed/NCBI
21	Palatnik JF, Wollmann H, Schommer C, Schwab R, Boisbouvier J, Rodriguez R, Warthmann N, Allen E, Dezulian T, Huson D, et al: Sequence and expression differences underlie functional specialization of Arabidopsis microRNAs miR159 and miR319. Dev Cell. 13:115–125. 2007. View Article : Google Scholar : PubMed/NCBI
22	Yamaki T, Suenaga Y, Iuchi T, Alagu J, Takatori A, Itami M, Araki A, Ohira M, Inoue M, Kageyama H, et al: Temozolomide suppresses MYC via activation of TAp63 to inhibit progression of human glioblastoma. Sci Rep. 3:11602013. View Article : Google Scholar : PubMed/NCBI
23	Loljung L, Coates PJ, Nekulova M, Laurell G, Wahlgren M, Wilms T, Widlöf M, Hansel A and Nylander K: High expression of p63 is correlated to poor prognosis in squamous cell carcinoma of the tongue. J Oral Pathol Med. 43:14–19. 2014. View Article : Google Scholar : PubMed/NCBI
24	Bahnassy AA, Zekri AR, Salem SE, Abou-Bakr AA, Sakr MA, Abdel-Samiaa AG and Al-Bradei M: Differential expression of p53 family proteins in colorectal adenomas and carcinomas: Prognostic and predictive values. Histol Histopathol. 29:207–216. 2014.PubMed/NCBI
25	Spiesbach K, Tannapfel A, Mössner J and Engeland K: TAp63gamma can substitute for p53 in inducing expression of the maspin tumor suppressor. Int J Cancer. 114:555–562. 2005. View Article : Google Scholar : PubMed/NCBI
26	Lv LV, Zhou J, Lin C, Hu G, Yi LU, Du J, Gao K and Li X: DNA methylation is involved in the aberrant expression of miR-133b in colorectal cancer cells. Oncol Lett. 10:907–912. 2015.PubMed/NCBI
27	Tahiri A, Leivonen SK, Lüders T, Steinfeld I, Aure M Ragle, Geisler J, Mäkelä R, Nord S, Riis ML, Yakhini Z, et al: Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis. 35:76–85. 2014. View Article : Google Scholar : PubMed/NCBI
28	Ren J, Huang HJ, Gong Y, Yue S, Tang LM and Cheng SY: MicroRNA-206 suppresses gastric cancer cell growth and metastasis. Cell Biosci. 4:262014. View Article : Google Scholar : PubMed/NCBI
29	Zhang Z, Kim K, Li X, Moreno M, Sharp T, Goodheart MJ, Safe S, Dupuy AJ and Amendt BA: MicroRNA-26b represses colon cancer cell proliferation by inhibiting lymphoid enhancer factor 1 expression. Mol Cancer Ther. 13:1942–1951. 2014. View Article : Google Scholar : PubMed/NCBI
30	Chen AX, Yu KD, Fan L, Li JY, Yang C, Huang AJ and Shao ZM: Germline genetic variants disturbing the Let-7/LIN28 double-negative feedback loop alter breast cancer susceptibility. PLoS Genet. 7:e10022592011. View Article : Google Scholar : PubMed/NCBI